BMC RheumatologyPub Date : 2026-11-03DOI: 10.1186/s41927-026-00710-3
Per Lewander, Diana Atanasova, Charlotte Dahle, Jonas Wetterö, Christopher Sjöwall, Per Magnusson
{"title":"Juvenile idiopathic arthritis is associated with reduced levels of biochemical bone status indices reflecting altered bone formation.","authors":"Per Lewander, Diana Atanasova, Charlotte Dahle, Jonas Wetterö, Christopher Sjöwall, Per Magnusson","doi":"10.1186/s41927-026-00710-3","DOIUrl":"10.1186/s41927-026-00710-3","url":null,"abstract":"<p><strong>Introduction: </strong>Individuals with juvenile idiopathic arthritis (JIA) are at increased risk of impaired bone health and fractures. This prospective case-control study assessed bone mineral density (BMD) and bone and cartilage biomarkers in children with JIA and healthy controls.</p><p><strong>Methods: </strong>Fifty-one individuals with well-characterized JIA (age 1.6-17.9 years) and 61 age-matched controls from the same region were included. Joint erosions were assessed radiographically, and BMD was measured by digital X-ray radiogrammetry (DXR). Bone formation was assessed using serum intact procollagen type I N-propeptide (PINP) and bone-specific alkaline phosphatase (BALP), and bone resorption was assessed by C-terminal telopeptide of type I collagen (CTX). Cartilage synthesis was assessed by serum type II procollagen C-terminal propeptide (PIICP). Biomarkers were measured at baseline and 1-year follow-up, while joint erosions were evaluated up to 5 years. Soluble urokinase plasminogen activator receptor (a.k.a. suPAR), rheumatoid factor, anti-cyclic citrullinated peptide antibodies, and antinuclear antibodies were also measured.</p><p><strong>Results: </strong>The DXR Z-scores were lower in the polyarticular subtype JIA group in comparison with controls (p = 0.010). The polyarticular JIA group had lower PINP levels in comparison with controls at inclusion (p = 0.028) and after 1 year (p = 0.006). Serum BALP levels were lower in the overall JIA group and in the polyarticular group at 1 year, p = 0.031 and p = 0.042, respectively. Plasma CTX levels were lower in individuals receiving oral steroids compared with those not receiving steroid therapy (p = 0.006). Higher PIICP levels were found in the oligoarticular subtype JIA group in comparison with the control group (p = 0.020).</p><p><strong>Conclusions: </strong>Based on our findings, children with JIA, particularly those with polyarticular disease, are at increased risk of compromised bone health over time, potentially related to reduced bone formation. These findings underscore the importance of monitoring bone health and implementing targeted interventions to promote optimal peak bone mass acquisition in children with JIA.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"10 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13729279/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149318039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BMC RheumatologyPub Date : 2026-10-14DOI: 10.1186/s41927-026-00707-y
Andreas Reich, Anja Weiß, Lisa Lindner, Martin Feuchtenberger, Georg Dahmen, Hanns-Martin Lorenz, Xenofon Baraliakos, Anne C Regierer
{"title":"Depressive symptoms are associated with achieving remission in PsA patients - an analysis from the RABBIT-SpA register.","authors":"Andreas Reich, Anja Weiß, Lisa Lindner, Martin Feuchtenberger, Georg Dahmen, Hanns-Martin Lorenz, Xenofon Baraliakos, Anne C Regierer","doi":"10.1186/s41927-026-00707-y","DOIUrl":"10.1186/s41927-026-00707-y","url":null,"abstract":"<p><strong>Background: </strong>Depressive symptoms are common in psoriatic arthritis (PsA) and may influence treatment response. This study examined their association with achieving remission after starting a new systemic antirheumatic therapy, and tested whether this association differs by sex.</p><p><strong>Methods: </strong>Data from PsA patients in the ongoing prospective longitudinal observational cohort study RABBIT-SpA were analyzed. Depressive symptoms were assessed with the WHO-5 Well-Being Index (none/mild vs. moderate/severe). Outcomes included minimal disease activity (MDA) and Disease Activity in Psoriatic Arthritis (DAPSA) remission at 3 and 6 months. Logistic regression assessed the association between baseline well-being and remission, adjusted for confounders identified using directed acyclic graphs. A sex × well-being interaction term was included in each model to test whether this association differs by sex. Multiple imputation handled missing data.</p><p><strong>Results: </strong>Moderate/severe depressive symptoms were present in 29% of 1,888 patients (34% of women, 23% of men). In adjusted analyses, higher baseline well-being was associated with remission (OR per 10-point increase: 1.06-1.14 across outcomes and timepoints, reaching significance for MDA at 6 months and DAPSA remission at both timepoints). Interaction testing showed no evidence that this association differed by sex; all four 95% confidence intervals included 1 (p ≥ 0.29). Both sexes with moderate/severe symptoms achieved MDA and DAPSA remission less frequently than those with no/mild symptoms. Although disease activity improved in both groups over time, it remained higher in patients with moderate/severe symptoms.</p><p><strong>Conclusions: </strong>Depressive symptoms were associated with higher disease activity and less frequent remission in PsA, with no evidence that this effect differed by sex. Routine screening for depressive symptoms should be considered in PsA management to identify patients at risk of suboptimal treatment response.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"10 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13670693/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149191248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BMC RheumatologyPub Date : 2026-09-29DOI: 10.1186/s41927-026-00698-w
Mohaned A Hameed, Sofia Exarchou, Ankita Sharma, Ulf Bergström, Jon T Einarsson, Carl Turesson
{"title":"Predictors at diagnosis for initiation of biologic or targeted synthetic disease-modifying anti-rheumatic drugs in patients with spondyloarthritis and psoriatic arthritis.","authors":"Mohaned A Hameed, Sofia Exarchou, Ankita Sharma, Ulf Bergström, Jon T Einarsson, Carl Turesson","doi":"10.1186/s41927-026-00698-w","DOIUrl":"10.1186/s41927-026-00698-w","url":null,"abstract":"<p><strong>Background: </strong>There is limited data on factors predicting the initiation of biologic and targeted synthetic disease modifying anti-rheumatic drugs (bDMARDs/tsDMARDs) in Spondyloarthritis (SpA) and Psoriatic arthritis (PsA). The relative importance of objective inflammation and other patient factors in this context is unclear.</p><p><strong>Methods: </strong>A retrospective cohort study included consecutive patients diagnosed with SpA and PsA in 2012-2016 at a single rheumatology center. Data at diagnosis were obtained from medical records and from linkage to national and regional registers. Baseline predictors of b/tsDMARD initiation were assessed by Cox regression.</p><p><strong>Results: </strong>Among 119 PsA patients (mean age 49 years, 49% male), 41.7% initiated b/tsDMARDs (median 15 months after diagnosis). In patients with PsA, older age was negatively associated with b/tsDMARD initiation (hazard ratio (HR) per standard deviation 0.74; 95% confidence interval (CI) 0.55-1.00), but no other significant predictors were identified. Among 120 SpA patients (mean age 38 years, 64% male), 41.5% initiated bDMARDs (median 7 months after diagnosis). Predictors included elevated CRP levels (HR 2.68; 95% CI 1.44-5.01) and bone marrow edema (BME) on magnetic resonance imaging of sacroiliac joints (SIJ) (HR 1.94; 95% CI 1.02-3.70). There was no significant association with age at SpA diagnosis, or with sex, education, family background, country of birth, or comorbidities.</p><p><strong>Conclusions: </strong>Elevated CRP and SIJ BME at diagnosis were associated with bDMARD initiation in patients with SpA, while older patients with PsA may be less likely to start b/tsDMARDs. Education and ethnicity did not seem to influence b/tsDMARD initiation, suggesting equitable treatment access.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"10 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13621707/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149079836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Longitudinal clinical outcomes after the escalation of subcutaneous tocilizumab from every 2 weeks to once weekly in rheumatoid arthritis with inadequate disease control: A 52-week real-world observational study.","authors":"Masanori Sudo, Sayuri Takamura, Asami Abe, Hajime Ishikawa, Daisuke Kobayashi, Kiyoshi Nakazono, Akira Murasawa, Suguru Yamamoto, Satoshi Ito","doi":"10.1186/s41927-026-00696-y","DOIUrl":"10.1186/s41927-026-00696-y","url":null,"abstract":"<p><strong>Background: </strong>To describe 52-week longitudinal clinical outcomes after escalation of subcutaneous tocilizumab (TCZ-SC) from every 2 weeks (Q2W) to once weekly (Q1W) in rheumatoid arthritis (RA) patients with inadequate clinical control during Q2W dosing, and contextualize findings using a TCZ-SC Q2W continuation cohort.</p><p><strong>Methods: </strong>This single-center retrospective observational study included 58 patients with RA who escalated from TCZ-SC Q2W to Q1W. The primary outcome was the overall longitudinal change in the Clinical Disease Activity Index (CDAI) through week 52, assessed using a complete-case Friedman test. Linear mixed-effects models using all available observations were fitted as sensitivity analyses. Secondary analyses included the Disease Activity Score in 28 joints using the erythrocyte sedimentation rate (DAS28-ESR), matrix metalloproteinase-3 (MMP-3), laboratory safety and renal outcomes, re-adjudicated difficult-to-treat (D2T) RA status, follow-up disposition, individual-level concomitant treatment intensification, and a Q2W continuation contextual comparison.</p><p><strong>Results: </strong>The median CDAI decreased from 16.00 at Q1W escalation to 8.20 at week 52 (complete-case Friedman test, n = 42, P < 0.001). In mixed-effects sensitivity analyses, model-estimated week-52 changes were - 5.89 points for CDAI (95% CI, - 8.15 to - 3.63), - 1.29 points for DAS28-ESR (95% CI, - 1.63 to - 0.95), - 45.8% for MMP-3 (95% CI, - 54.9% to - 34.7%), and - 4.79 mL/min/1.73 m<sup>2</sup> for estimated glomerular filtration rate (eGFR) (95% CI, - 7.65 to - 1.92). Five patients (8.6%) fulfilled the stricter D2T RA definition. Fifteen patients lacked week-52 CDAI data because of Q1W discontinuation or interruption (n = 13) or transfer of care (n = 2); the incomplete follow-up group had higher baseline disease activity. Seven patients had documented regular systemic treatment intensification during weeks 0-12; after excluding them, the median 12-week ΔCDAI remained - 3.00 (P < 0.001). In the exploratory 12-week comparison, the median ΔCDAI was - 2.85 in the Q1W escalation cohort and - 3.40 in the Q2W residual-activity subgroup, with no significant between-group difference (P = 0.754). No serious infections or treatment discontinuations due to adverse events were documented.</p><p><strong>Conclusions: </strong>Disease activity decreased after Q1W escalation, with directionally consistent sensitivity analyses. However, the 12-week CDAI changes did not differ significantly between the Q1W escalation cohort and the Q2W residual-activity subgroup. These descriptive findings do not establish an incremental or causal benefit of Q1W escalation.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"10 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13617787/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149073464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BMC RheumatologyPub Date : 2026-09-14DOI: 10.1186/s41927-026-00694-0
Iván Ferraz-Amaro, Juan Carlos Quevedo-Abeledo, Beatriz Tejera-Segura, Enrique García-Barrera, Luisa María Villar, Javier Gonzalo Ocejo-Vinyals, Raquel Largo, Miguel Ángel González-Gay
{"title":"Ultrasensitive serum levels of interleukin 13 in systemic lupus erythematosus patients: a cross-sectional study.","authors":"Iván Ferraz-Amaro, Juan Carlos Quevedo-Abeledo, Beatriz Tejera-Segura, Enrique García-Barrera, Luisa María Villar, Javier Gonzalo Ocejo-Vinyals, Raquel Largo, Miguel Ángel González-Gay","doi":"10.1186/s41927-026-00694-0","DOIUrl":"10.1186/s41927-026-00694-0","url":null,"abstract":"<p><strong>Background: </strong>Systemic lupus erythematosus (SLE) is characterized by elevated levels of various cytokines. Interleukin (IL)-13 is a pleiotropic type 2 cytokine that plays a central role in allergic inflammation and tissue fibrosis. Until recently, serum measurement of IL-13 was not feasible because of its extremely low concentration. New highly sensitive techniques now allow its quantification at the femtogram level. In the present study, we aimed to evaluate the association between SLE-disease characteristics and ultrasensitive serum IL-13 levels.</p><p><strong>Methods: </strong>In this cross-sectional study, a comprehensive characterization of 313 patients with SLE was performed, including autoantibody profiles and indices of disease activity (SLE-DAS, SLEDAI-2 K, and LLDAS), damage (SLICC-DI), and remission (DORIS). In addition, the cohort was evaluated with complete hematological and lipid profiles, insulin resistance indices, and assessment of subclinical carotid atherosclerosis and carotid stiffness. Serum IL-13 levels were measured using the Simoa (Single Molecule Array) technique. Multivariable linear regression analyses were then conducted to examine the associations between these disease characteristics and circulating IL-13.</p><p><strong>Results: </strong>In multivariable regression analyses demographic features, disease activity indices (SLEDAI-2 K, SLE-DAS, DORIS), damage scores, overall disease duration, autoantibodies and interferon or complement levels were not associated with IL-13. However, in the adjusted models, neutrophil and platelet counts showed an inverse association with IL-13. It was also the case for metabolic factors, as higher levels of HDL-cholesterol and apolipoprotein A1 were independently associated with lower IL-13 levels, while a higher LDL: HDL ratio, a higher ApoB: ApoA1 ratio, and a higher atherogenic index were associated with superior IL-13 levels. In contrast, augmentation index was inversely and independently associated with IL-13.</p><p><strong>Conclusions: </strong>Serum IL-13 levels are not associated with key SLE-related features such as disease activity or the autoantibodies profile. Since IL-13 was associated with an adverse lipid profile, its inverse relationship with augmentation index suggests that its cardiovascular effects may be at least partially independent of circulating lipids. These apparently divergent associations likely reflect distinct but interconnected pathways through which IL-13 influences cardiovascular risk in SLE.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"10 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13679122/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149223346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BMC RheumatologyPub Date : 2026-08-28DOI: 10.1186/s41927-026-00684-2
Dorothea Reck, Jörg Christoph Henes, Sebastian Jonas Saur
{"title":"Clinical and genetic characteristics of adult patients with familial Mediterranean fever at a German tertiary referral centre.","authors":"Dorothea Reck, Jörg Christoph Henes, Sebastian Jonas Saur","doi":"10.1186/s41927-026-00684-2","DOIUrl":"10.1186/s41927-026-00684-2","url":null,"abstract":"<p><strong>Objective: </strong>To characterise the clinical and genetic profile of adult familial Mediterranean fever (FMF) patients at a German tertiary referral centre and examine genotype-phenotype associations.</p><p><strong>Methods: </strong>In this prospective single-centre registry study (October 2019-March 2021), 95 adult FMF patients at University Hospital Tübingen were evaluated using structured questionnaires and medical record review. All patients had a pre-existing clinical diagnosis of FMF based on the Tel Hashomer and/or Eurofever/PRINTO criteria. Demographic data, clinical manifestations, treatment, and MEFV mutations were analysed. Patients were stratified by mutation status (homozygous M694V, heterozygous/compound-heterozygous M694V, other mutations). Statistical analyses included the Fisher-Freeman-Halton exact test and ANOVA. Variants were classified according to the INSAID consensus classification; R202Q was treated as a benign polymorphism. All subgroup comparisons were exploratory and were not corrected for multiple testing.</p><p><strong>Results: </strong>Median age was 36 years, with median symptom onset at 10 years. Most patients were of Turkish origin (74.7%), and 59.6% reported a family history of FMF. Common manifestations included abdominal pain (90.5%), arthralgia/arthritis (75.8%), fever (66.3%), and chest pain (52.6%). Colchicine was used in 96.8% of patients, while 38.3% received biologic therapy, a figure influenced by concurrent participation in a tocilizumab trial at our centre. MEFV analysis had been performed in 91 of the 95 patients (95.8%); among these, at least one MEFV variant was detected in 87 (95.6%), with M694V being the most frequent variant (61.5%). Homozygous M694V patients showed earlier disease onset (nominal p = 0.02) and higher rates of arthralgia/arthritis (nominal p = 0.035). Amyloidosis occurred in one patient with homozygous M694V.</p><p><strong>Conclusion: </strong>This cohort demonstrates typical FMF features with a predominance of the M694V mutation. Homozygosity for M694V is associated with earlier disease onset and increased musculoskeletal involvement. Subgroup findings are exploratory and require confirmation in independent cohorts.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"10 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13523296/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148849862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BMC RheumatologyPub Date : 2026-08-17DOI: 10.1186/s41927-026-00683-3
Myroslava Kulyk, Nataliia Grygorieva, Anna Musiienko, Marta Dzhus
{"title":"Bone mineral density, body composition, and muscle strength in young adults with juvenile idiopathic arthritis: a case-control study.","authors":"Myroslava Kulyk, Nataliia Grygorieva, Anna Musiienko, Marta Dzhus","doi":"10.1186/s41927-026-00683-3","DOIUrl":"https://doi.org/10.1186/s41927-026-00683-3","url":null,"abstract":"<p><strong>Background: </strong>Juvenile idiopathic arthritis (JIA) frequently leads to musculoskeletal complications that persist into adulthood. This study aimed to comprehensively assess bone mineral density (BMD), body composition, and muscle strength in young adults with JIA compared with healthy controls.</p><p><strong>Methods: </strong>In this cross-sectional case-control study, 147 participants (81 JIA patients, 66 healthy controls) were evaluated. BMD and body composition were assessed via dual-energy X-ray absorptiometry; muscle strength was measured by handgrip strength (HGS) dynamometry. Sarcopenia was defined according to the European Working Group on Sarcopenia in Older People (EWGSOP2) criteria. Data were analyzed using analysis of covariance (ANCOVA) adjusted for age, sex, and height. Adjusted odds ratios (OR) for sarcopenia and low BMD (Z-score ≤ - 2.0) were calculated using Firth's penalized logistic regression to account for age and sex.</p><p><strong>Results: </strong>Patients with JIA had significantly lower BMD at all sites (p < 0.01), with the largest deficit in total forearm BMD (0.524 ± 0.094 vs. 0.691 ± 0.100 g/cm², p < 0.001). JIA patients also showed a significantly lower skeletal muscle index (SMI) (6.05 ± 1.52 vs. 6.89 ± 1.19 kg/m², p < 0.001) and markedly reduced HGS (18.0 [14.0; 25.0] vs. 25.5 [22.0; 37.5] kg, p < 0.001). Sarcopenia was present in 54% of JIA patients and 0% of controls (p < 0.001). A significant mass-strength dissociation was identified: in patients with low disease activity (LDA) (defined by the Juvenile Arthritis Disease Activity Score-27 [JADAS27]), SMI was comparable to controls (6.99 ± 1.47 vs. 6.89 ± 1.19 kg/m², p = 1.00), yet their HGS remained significantly lower (22.0 [18.0; 29.0] vs. 25.5 [22.0; 37.5] kg, p < 0.001). Overall, JIA was associated with much higher odds of sarcopenia (aOR 107.8) and low BMD (aOR 13.6).</p><p><strong>Conclusion: </strong>Young adults with JIA demonstrated lower BMD, reduced lean mass and muscle strength compared with healthy controls, with persistent muscle strength impairment even in patients with relatively preserved muscle mass and low disease activity. These comparisons should be interpreted in light of the age difference between the JIA and control groups.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"10 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13756939/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149401898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BMC RheumatologyPub Date : 2026-08-14DOI: 10.1186/s41927-026-00681-5
Daphne To, Jenna C Wong, Celia Laur, Laura Oliva, Zeenat Ladak, Laura Passalent, J Carter Thorne, Jessica Widdifield, Lauren K King
{"title":"Considerations for optimal team-based rheumatology care: a qualitative study exploring the experiences of rheumatology health professionals.","authors":"Daphne To, Jenna C Wong, Celia Laur, Laura Oliva, Zeenat Ladak, Laura Passalent, J Carter Thorne, Jessica Widdifield, Lauren K King","doi":"10.1186/s41927-026-00681-5","DOIUrl":"10.1186/s41927-026-00681-5","url":null,"abstract":"<p><strong>Background: </strong>Interdisciplinary team-based rheumatology care models are a promising solution for improving access to high quality, equitable care for people with rheumatic and musculoskeletal disorders. There is limited understanding on health professionals' perspectives on their needs to deliver care under this model. We explored rheumatology team members' perceptions on individual and practice features required for optimal team-based care.</p><p><strong>Methods: </strong>We conducted a qualitative descriptive study using secondary analysis of semi-structured interviews with rheumatologists (n = 3), interdisciplinary health professionals (IHPs) (n = 7), and administrators (n = 5) in an interdisciplinary rheumatology team in Ontario, Canada. Interviews explored team members' experience working within the team and the health professional and clinic characteristics they perceived as necessary for optimal team-based care. We coded interview transcripts inductively and constructed themes using thematic analysis.</p><p><strong>Results: </strong>We identified three themes: (1) Key health professional qualities; (2) Synergy of complementary skillsets; and (3) Supportive operational structures. Participants felt that health professionals must acquire rheumatology-specific training in addition to bringing discipline-specific skillsets to work collaboratively to meet patients' needs. They perceived that their complementary skillsets benefited patients (e.g., better clinical outcomes) and was also professionally rewarding. Participants emphasised the importance of operational structures necessary for optimal team-based rheumatology care, including shared workspaces and electronic medical records, competitive compensation, and stable funding.</p><p><strong>Conclusions: </strong>Rheumatology team members highlighted key considerations for health professionals and practices when developing optimal team-based rheumatology practices. This study offers insights to support policy, practice, and health system-level efforts to spread and scale team-based rheumatology care models.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"10 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13753084/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149385423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Glucocorticoid tapering and clinical outcomes during belimumab treatment in systemic lupus erythematosus: a retrospective real-world cohort study with exploratory renal analyses.","authors":"Masanori Sudo, Sahoko Otsuka, Sayuri Takamura, Daisuke Kobayashi, Asami Abe, Hajime Ishikawa, Kiyoshi Nakazono, Akira Murasawa, Masaki Yonezawa, Masato Habuka, Asa Ogawa, Yumi Ito, Naofumi Imai, Suguru Yamamoto, Satoshi Ito","doi":"10.1186/s41927-026-00680-6","DOIUrl":"10.1186/s41927-026-00680-6","url":null,"abstract":"<p><strong>Background: </strong>To describe real-world clinical outcomes of belimumab (BEL) treatment in patients with systemic lupus erythematosus (SLE), with a particular focus on longitudinal glucocorticoid tapering and exploratory renal analyses.</p><p><strong>Methods: </strong>This single-center retrospective observational study included 46 patients with SLE who initiated BEL treatment between 2018 and 2025. Clinical and laboratory data, including prednisolone (PSL) dose, disease activity indices, serological markers, urine protein-to-creatinine ratio (UPCR), and estimated glomerular filtration rate (eGFR), were collected at baseline and during follow-up, when available. Longitudinal changes in concomitant background therapies were summarized descriptively. Exploratory renal analyses were performed in patients with lupus nephritis (LN) using changes in the UPCR and eGFR. Drug retention was evaluated using the Kaplan-Meier method. Renal histopathological analyses were performed in a subset with available biopsy data and were considered exploratory because of the heterogeneous clinical backgrounds and variable biopsy timing.</p><p><strong>Results: </strong>The median PSL dose decreased from 10 mg/day at baseline to 8 mg/day at 24 weeks and 6 mg/day at 52 weeks after BEL initiation, with significant within-patient decreases at both time points (p < 0.001). Overall disease activity remained controlled, while complement levels improved during the follow-up. Among patients with LN (n = 12), UPCR showed a numerical decrease at 24 weeks (p = 0.055) and decreased at 52 weeks (p = 0.016) among patients with paired data, whereas the eGFR showed no significant change at either time point. Exploratory analyses did not identify significant associations between the available renal histopathological indices and changes in proteinuria. BEL treatment was continued in many patients during follow-up, although adverse events, including severe infections and death, were observed.</p><p><strong>Conclusions: </strong>In this real-world cohort, PSL doses decreased during follow-up after the initiation of BEL, while the overall disease activity remained controlled. In the small LN subgroup, the UPCR decreased at 52 weeks, and no statistically significant change in eGFR was detected. Because this study lacked a comparator group and the renal analyses were exploratory and limited by the small sample size, heterogeneous treatment backgrounds, and variable biopsy timing, these findings should be interpreted as within-patient observational data and require validation in future studies.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"10 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13595690/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149023781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BMC RheumatologyPub Date : 2026-07-31DOI: 10.1186/s41927-026-00679-z
Meiqi Chen, Xiang Gao
{"title":"The causal association between Celiac disease and Ankylosing spondylitis: a two-sample Mendelian randomization analysis.","authors":"Meiqi Chen, Xiang Gao","doi":"10.1186/s41927-026-00679-z","DOIUrl":"10.1186/s41927-026-00679-z","url":null,"abstract":"<p><strong>Objective: </strong>The concept of the gut-joint axis is often mentioned when exploring the pathogenesis of Ankylosing spondylitis (AS). This study aims to explore whether there is a causal association between Celiac disease (CeD) and AS.</p><p><strong>Method: </strong>Two-sample Mendelian randomization (MR) analysis was conducted using the CeD dataset (the largest pure CeD phenotype dataset in the IEU OpenGWAS database at the time of data retrieval, n = 24,269) and the AS dataset (strictly defined, from the IEU OpenGWAS database, n = 218,030). Inverse Variance Weighting (IVW) was adopted as the primary MR analysis method, supplemented by Weighted Median Estimator, MR-Egger regression, Simple Mode, and Weighted Mode to comprehensively evaluate the causal association between CeD and AS. Additionally, horizontal pleiotropy, heterogeneity, and leave-one-out analysis were performed to further evaluate the robustness and reliability of the results.</p><p><strong>Results: </strong>IVW analysis showed a positive causal effect of genetically predicted CeD on AS (OR: 1.435, 95% CI: 1.210-1.702, p = 3.34E-05), and the other four analytical methods also yielded consistent causal effect evaluation results. No significant horizontal pleiotropy or heterogeneity was observed in this study.</p><p><strong>Conclusion: </strong>MR analysis indicates that CeD may be a potential risk factor for AS, providing genetic evidence for the increased risk of AS in individuals with a genetic predisposition to CeD.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"10 1","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13678970/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149223376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}